Interferon therapy for patients more than 60 years of age with chronic hepatitis C. 1995

N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
Third Department of Internal Medicine, Ehime University School of Medicine, Japan.

Nineteen patients aged > 60 years with chronic hepatitis C (CHC) received interferon (IFN) therapy and a complete response (CR) was achieved by five of them (26%). The incidence of CH with severe fibrosis in this elderly group was significantly higher than in another 52 patients with CHC who were < 60 years of age (the younger group; P < 0.05). There was no significant difference in the hepatitis C virus (HCV) genotype distribution between the elderly group and the younger group. However, the HCV-RNA titre was significantly higher in the elderly group than in the younger group (P < 0.05). There was no significant difference in the efficacy rate of IFN in the elderly and younger groups after standardization of the background factors. In the elderly group, the HCV-RNA titre was significantly lower in the patients achieving CR than in those with no response (P < 0.05). These data suggest that elderly patients with a low HCV-RNA titre can still respond well to IFN therapy.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
August 2000, Hepatology (Baltimore, Md.),
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
May 2010, Oncology letters,
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
July 2007, Journal of gastroenterology and hepatology,
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
July 1955, Journal of neurosurgery,
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
February 1989, Transplantation,
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
August 2021, Expert review of anti-infective therapy,
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
November 1965, American journal of obstetrics and gynecology,
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
June 2007, Hepatology (Baltimore, Md.),
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
June 2012, Chinese medical journal,
N Horiike, and T Masumoto, and K Nakanishi, and K Michitaka, and K Kurose, and I Ohkura, and M Onji
July 1996, Bailliere's clinical gastroenterology,
Copied contents to your clipboard!